Aptorum Group Limited Class A Ordinary Shares (APM)
Aptorum Group Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies in areas such as infectious diseases, oncology, and metabolic disorders. The company leverages its expertise in drug discovery and development, primarily through its research and development subsidiaries, to bring novel treatments to market. Based in Hong Kong, Aptorum aims to address unmet medical needs through its pipeline of clinical-stage and preclinical products.
Company News
DiamiR Biosciences received New York State approval for its APOE Genotyping test, which identifies genetic variants associated with late-onset Alzheimer's disease risk. The company is set to merge with Aptorum Group in an all-stock transaction expected to close in Q4 2025.
Aptorum Group, a clinical-stage biopharmaceutical company, announced a $3 million registered direct offering of 1,535,000 Class A Ordinary Shares at $2.00 per share. The offering is expected to close on January 3, 2025, subject to customary closing conditions.
Bank of America 'scarcity' stock picks target chip bottlenecks, water, lithium, a circular economy, ESG and human capital, to name a few.
4 penny stocks outperforming Facebook Meta stock today The post 4 Penny Stocks To Buy For Under $5 Outperforming FB Stock In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.